Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study-Reference-Cited by-同舟云学术

Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study

Published:2024-09 Issue:9 Volume:9 Page:e654-e663
ISSN:2468-2667
Container-title:The Lancet Public Health
language:en
Short-container-title:The Lancet Public Health

Author:

Choi Yoon Hong,Bertran Marta,Litt David J,Ladhani Shamez N,Miller Elizabeth

Funder

National Institute for Health Research

Publisher

Elsevier BV

Reference28 articles.

1. The pneumococcus: epidemiology, microbiology, and pathogenesis;Henriques-Normark;Cold Spring Harb Perspect Med,2013

2. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens;Daniels;J Pediatr Pharmacol Ther,2016

3. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study;Ladhani;Lancet Infect Dis,2018

4. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial;Goldblatt;Lancet Infect Dis,2018

5. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study;Choi;PLoS Med,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New-generation pneumococcal vaccines for children;The Lancet Public Health;2024-09